These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

247 related items for PubMed ID: 6450277

  • 1. Clinical evaluation of a new broad-spectrum oxa-beta-lactam antibiotic, moxalactam, in neonates and infants.
    Schaad UB, McCracken GH, Threlkeld N, Thomas ML.
    J Pediatr; 1981 Jan; 98(1):129-36. PubMed ID: 6450277
    [Abstract] [Full Text] [Related]

  • 2. Successful moxalactam therapy for gram-negative bacillary meningitis in neonates.
    Ramos OM, Kaplan SL, Mason EO, Denson S, Pickering LK.
    South Med J; 1982 May; 75(5):632-3. PubMed ID: 6210970
    [Abstract] [Full Text] [Related]

  • 3. Relapse of Escherichia coli meningitis following therapy with moxalactam.
    Broughton RA, Mason EO, Baker CJ.
    Pediatr Infect Dis; 1982 May; 1(1):24-8. PubMed ID: 6217454
    [Abstract] [Full Text] [Related]

  • 4. Pharmacokinetics and bacteriological efficacy of moxalactam (LY127935), netilmicin, and ampicillin in experimental gram-negative enteric bacillary meningitis.
    Schaad UB, McCracken GH, Loock CA, Thomas ML.
    Antimicrob Agents Chemother; 1980 Mar; 17(3):406-11. PubMed ID: 6448576
    [Abstract] [Full Text] [Related]

  • 5. Moxalactam (LY127935) in treatment of meningitis due to gram-negative bacilli.
    Fisher JF, Carter MJ, Parsons J, Rissing JP.
    Antimicrob Agents Chemother; 1981 Feb; 19(2):218-21. PubMed ID: 6214985
    [Abstract] [Full Text] [Related]

  • 6. Diffusion of a new beta-lactam (LY 127935) into cerebrospinal fluid. Implications for therapy of gram-negative bacillary meningitis.
    Landesman SH, Corrado ML, Cherubin CC, Gombert M, Cleri D.
    Am J Med; 1980 Jul; 69(1):92-8. PubMed ID: 6446240
    [Abstract] [Full Text] [Related]

  • 7. Successful treatment of gram-negative bacillary meningitis with moxalactam.
    Olson DA, Hoeprich PD, Nolan SM, Goldstein E.
    Ann Intern Med; 1981 Sep; 95(3):302-5. PubMed ID: 6455950
    [Abstract] [Full Text] [Related]

  • 8. Pharmacokinetics and bacteriologic efficacy of moxalactam, cefotaxime, cefoperazone, and rocephin in experimental bacterial meningitis.
    Schaad UB, McCracken GH, Loock CA, Thomas ML.
    J Infect Dis; 1981 Feb; 143(2):156-63. PubMed ID: 6260870
    [Abstract] [Full Text] [Related]

  • 9. In vitro and in vivo antibacterial activity of moxalactam, an oxa-beta-lactam antibiotic.
    Goto S.
    Rev Infect Dis; 1982 Feb; 4 Suppl():S501-10. PubMed ID: 6218559
    [Abstract] [Full Text] [Related]

  • 10. New drug evaluations: moxalactam (Moxam, Eli Lilly).
    Polk RE.
    Drug Intell Clin Pharm; 1982 Feb; 16(2):104-12. PubMed ID: 6210519
    [Abstract] [Full Text] [Related]

  • 11. A comparative evaluation of moxalactam: antimicrobial activity, pharmacokinetics, adverse reactions, and clinical efficacy.
    Fitzpatrick BJ, Standiford HC.
    Pharmacotherapy; 1982 Feb; 2(4):197-212. PubMed ID: 6221237
    [Abstract] [Full Text] [Related]

  • 12. Pharmacokinetics of moxalactam and cefazolin compared in normal volunteers.
    Srinivasan S, Fu KP, Neu HC.
    Antimicrob Agents Chemother; 1981 Feb; 19(2):302-5. PubMed ID: 6214989
    [Abstract] [Full Text] [Related]

  • 13. Pharmacokinetics and cerebrospinal fluid penetration of moxalactam in children with bacterial meningitis.
    Kaplan SL, Mason EO, Garcia H, Kvernland SJ, Loiselle EM, Anderson DC, Mintz AA, Feigin RD.
    J Pediatr; 1981 Jan; 98(1):152-7. PubMed ID: 6450278
    [Abstract] [Full Text] [Related]

  • 14. [Experimental and clinical studies on 6059-S (author's transl)].
    Toyonaga Y, Sugita M, Kurosu Y, Kumagai K, Hori M, Takahashi T.
    Jpn J Antibiot; 1981 May; 34(5):764-81. PubMed ID: 6457175
    [Abstract] [Full Text] [Related]

  • 15. Third-generation cephalosporins: a critical evaluation.
    Barriere SL, Flaherty JF.
    Clin Pharm; 1984 May; 3(4):351-73. PubMed ID: 6432420
    [Abstract] [Full Text] [Related]

  • 16. Moxalactam therapy for gram-negative bacillary meningitis.
    Rahal JJ.
    Rev Infect Dis; 1982 May; 4 Suppl():S606-9. PubMed ID: 6218572
    [Abstract] [Full Text] [Related]

  • 17. Pharmacology and cerebrospinal fluid penetration of moxalactam in children and dosage recommendations.
    Kaplan SL, Mason EO, Kvernland SJ, Calaway EL, Feigin RD.
    Rev Infect Dis; 1982 May; 4 Suppl():S597-602. PubMed ID: 6218570
    [Abstract] [Full Text] [Related]

  • 18. Pharmacokinetics of moxalactam in neonates and young infants.
    McCracken GH, Schaad UB.
    Rev Infect Dis; 1982 May; 4 Suppl():S595-6. PubMed ID: 6218569
    [No Abstract] [Full Text] [Related]

  • 19. Mecillinam alone and in combination with ampicillin or moxalactam in experimental Escherichia coli meningitis.
    Schaad UB, Grimm LM, Beskid G, Cleeland R, Nelson JD, McCracken GH.
    Infection; 1982 May; 10(2):90-6. PubMed ID: 6284652
    [Abstract] [Full Text] [Related]

  • 20. Citrobacter meningitis and cerebral abscess in early infancy: cure by moxalactam.
    Levy RL, Saunders RL.
    Neurology; 1981 Dec; 31(12):1575-7. PubMed ID: 6458777
    [Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 13.